The treatment using monoclonal anti–ELTD1 antibody showed high binding specificity, increasing the lifespan, normalizing the vasculature and reducing the tumor volume, compared with the untreated or polyclonal–treated mice. Here, ADGRL4 is linked to neoplasm.